Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,938,229
  • Shares Outstanding, K 279,307
  • Annual Sales, $ 1,190 K
  • Annual Income, $ -444,040 K
  • 60-Month Beta 0.63
  • Price/Sales 3,300.47
  • Price/Cash Flow N/A
  • Price/Book 6.36
Trade IOVA with:

Options Overview Details

View History
  • Implied Volatility 112.72% ( -33.22%)
  • Historical Volatility 125.25%
  • IV Percentile 83%
  • IV Rank 21.93%
  • IV High 293.08% on 01/25/24
  • IV Low 62.06% on 09/20/23
  • Put/Call Vol Ratio 0.38
  • Today's Volume 13,711
  • Volume Avg (30-Day) 15,224
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 177,107
  • Open Int (30-Day) 250,268

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 7
  • High Estimate -0.40
  • Low Estimate -0.50
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.60 +8.97%
on 03/19/24
18.24 -18.75%
on 03/04/24
-2.61 (-14.97%)
since 02/28/24
3-Month
7.34 +101.91%
on 01/29/24
18.33 -19.15%
on 02/28/24
+6.24 (+72.73%)
since 12/28/23
52-Week
3.21 +361.68%
on 10/19/23
18.33 -19.15%
on 02/28/24
+8.61 (+138.65%)
since 03/28/23

Most Recent Stories

More News
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

Find out why investment banks up and down Wall Street have big expectations for these stocks.

LLY : 777.96 (-0.03%)
COMP : 3.60 (+3.75%)
VKTX : 82.00 (-1.61%)
IOVA : 14.82 (+5.11%)
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead

This company's growth story is about to get moving with gusto.

LLY : 777.96 (-0.03%)
IOVA : 14.82 (+5.11%)
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?

Its revenue is set to grow, and one of its trials is no longer paused.

IOVA : 14.82 (+5.11%)
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst

With its first approval in hand, attention is now on the top line.

GS : 417.69 (+0.59%)
IOVA : 14.82 (+5.11%)
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?

Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?

IOVA : 14.82 (+5.11%)
Why Iovance Biotherapeutics Stock Got Trounced on Thursday

A robust rally ended abruptly with the publication of the company's latest fundamentals.

IOVA : 14.82 (+5.11%)
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?

More gains might be on the way for this high-flying biotech stock.

IOVA : 14.82 (+5.11%)
Iovance Biotherapeutics: Q4 Earnings Snapshot

Iovance Biotherapeutics: Q4 Earnings Snapshot

IOVA : 14.82 (+5.11%)
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street

A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof.

IOVA : 14.82 (+5.11%)
Is Iovance a Buy After Its First Regulatory Win?

Iovance Biotherapeutics has found a new way to treat cancer.

IOVA : 14.82 (+5.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 16.38
2nd Resistance Point 15.78
1st Resistance Point 15.30
Last Price 14.82
1st Support Level 14.22
2nd Support Level 13.62
3rd Support Level 13.14

See More

52-Week High 18.33
Last Price 14.82
Fibonacci 61.8% 12.55
Fibonacci 50% 10.77
Fibonacci 38.2% 8.99
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar